Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.67 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.60 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.60 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.53 |
| ▸ | TLR2 | O60603 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | P2RY10 | O00398 | 6/20 | 0.47 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.47 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.47 |
| ▸ | FABP3 | P05413 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1962151 | 1.00 | PLA2G2C (0.67) | PLA2G2CLPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL12345678 | 1.00 | PLA2G2C (0.67) | PLA2G2CLPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL2233966 | 1.00 | PLA2G2C (0.67) | PLA2G2CLPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL12345664 | 1.00 | PLA2G2C (0.67) | PLA2G2CLPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL15166560 | 1.00 | PLA2G2C (0.67) | PLA2G2CLPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL12345694 | 1.00 | PLA2G2C (0.67) | PLA2G2CLPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL705428 | 1.00 | PLA2G2C (0.67) | PLA2G2CLPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL2175237 | 1.00 | PLA2G2C (0.67) | PLA2G2CLPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL12345706 | 1.00 | PLA2G2C (0.67) | PLA2G2CLPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL2234099 | 1.00 | PLA2G2C (0.67) | PLA2G2CLPAR1LPAR3LPAR2TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9968622-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2018-05-15 | — | — | US | disclosed |
| US-20170246197-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2017-08-31 | — | — | US | disclosed |
| US-9566288-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2017-02-14 | — | — | US | disclosed |
| US-20150216882-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2015-08-06 | — | — | US | disclosed |
| US-9006217-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2015-04-14 | — | — | US | disclosed |
| US-8802875-B2 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2014-08-12 | — | — | US | disclosed |
| US-8759557-B2 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2014-06-24 | — | — | US | disclosed |
| US-8569529-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-10-29 | — | — | US | disclosed |
| US-20130237720-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-09-12 | — | — | US | disclosed |
| US-20130190523-A1 | Process for the Preparation of Oxidized Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-07-25 | — | — | US | disclosed |
| US-20130158283-A1 | Process for the Preparation of Oxidized Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-06-20 | — | — | US | disclosed |
| US-20130079540-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-03-28 | — | — | US | disclosed |
| EP-2522672-A1 | Oxidized phospholipids | Vascular Biogenics Ltd. (IL) | 2012-11-14 | — | — | EP | disclosed |
| US-20120130108-A1 | PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | VASCULAR BIOGENICS LTD. (IL) | 2012-05-24 | — | — | US | disclosed |
| US-8124800-B2 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2012-02-28 | — | — | US | disclosed |
| US-20100317881-A1 | PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | VASCULAR BIOGENICS LTD. (IL) | 2010-12-16 | — | — | US | disclosed |
| US-7807847-B2 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2010-10-05 | — | — | US | disclosed |
| EP-2125838-A2 | IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | Vascular Biogenics Ltd. (IL) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008084472-A2 | IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | VASCULAR BIOGENICS LTD. (IL) | 2008-07-17 | — | — | WO | disclosed |
| US-20070112211-A1 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190523-A1 | Process for the Preparation of Oxidized Phospholipids | PHOSPHO1, SGMS1, SGMS2 | PLA2G2C 21/4885LPAR1 203/4885LPAR3 310/4885 |
| US-20100317881-A1 | PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | PHOSPHO1, SGMS1, SGMS2 | PLA2G2C 19/4885LPAR1 199/4885LPAR3 323/4885 |
| US-20130079540-A1 | High-Purity Phospholipids | PHOSPHO1, SGMS1, SGMS2 | PLA2G2C 14/4885LPAR1 77/4885LPAR3 114/4885 |
| US-20150216882-A1 | High-Purity Phospholipids | PHOSPHO1, SGMS1, SGMS2 | PLA2G2C 13/4885LPAR1 71/4885LPAR3 126/4885 |
| US-20130158283-A1 | Process for the Preparation of Oxidized Phospholipids | PHOSPHO1, SGMS1, SGMS2 | PLA2G2C 19/4885LPAR1 199/4885LPAR3 323/4885 |
| US-20170246197-A1 | High-Purity Phospholipids | PHOSPHO1, SGMS1, SGMS2 | PLA2G2C 13/4885LPAR1 71/4885LPAR3 126/4885 |
| US-20120130108-A1 | PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | PHOSPHO1, SGMS1, SGMS2 | PLA2G2C 19/4885LPAR1 199/4885LPAR3 323/4885 |
| US-20070112211-A1 | Process for the preparation of oxidized phospholipids | PHOSPHO1, SGMS1, SGMS2 | PLA2G2C 19/4885LPAR1 199/4885LPAR3 323/4885 |
| US-20130237720-A1 | High-Purity Phospholipids | PHOSPHO1, SGMS1, SGMS2 | PLA2G2C 13/4885LPAR1 71/4885LPAR3 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.